Amyris Biotechnologies Inc., an Emeryville, Calif.-based synthetic biology company focused on the development of pharmaceuticals, fine chemicals and biofuels, has raised $20 million in Series A funding. Khosla Ventures led the deal, and was joined by Kleiner Perkins Caufield & Byers and TPG Ventures. In related news, Amyris appointed John Melo as CEO. He previously was president of
Conduit Capital Partners of